Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

NCT03690141

terminatedphase_1

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

NCT02605083

completedphase_2

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

NCT03258398

terminatedphase_2

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

NCT03318562

Clinical Trials (4)

Showing 4 of 4 trials

NCT03690141Phase 2

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Terminated

NCT02605083Phase 1

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Terminated

NCT03258398Phase 2

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Completed

NCT03318562Phase 2

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4